Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bortezomib / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
  • Chromosomes, Human, Pair 11 / genetics
  • Chromosomes, Human, Pair 14 / genetics
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Plasma Cell / complications
  • Leukemia, Plasma Cell / drug therapy*
  • Leukemia, Plasma Cell / genetics
  • Leukemia, Plasma Cell / therapy
  • Male
  • Middle Aged
  • Molecular Targeted Therapy*
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm, Residual
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Recurrence
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Translocation, Genetic
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Neoplasm Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • venetoclax

Supplementary concepts

  • CVAD protocol